Rick Maffei

[Lung Cancer: Targets and Therapy] This research examines examine the clinical trial data that evaluated the combination of chemotherapy with immune checkpoint inhibitors for the front-line treatment of advanced NSCLC patients.

Guiding and educating patients throughout their cancer diagnosis and treatment.

[Cancer Management and Research] The aim of this study was to establish a prognostic estimation of CHCs after resection (PECAR) score predicting recurrence on the basis of the clinicopathological data.

[Cancer Management and Research] In this report, researchers review evidence to date on the effectiveness of immune checkpoint inhibitors in combination for the treatment of non-small cell lung cancer.

Coverage from this year’s ONA Navigation Summit.

The following article features coverage from the ONA 2019 Navigation Summit. Click here to read more of Oncology Nurse Advisor‘s conference coverage.

[Cancer Management and Research] A meta-analysis of randomized controlled trials sought to confirm the effectiveness and safety of olaparib for the treatment of relapsed BRCA-mutated ovarian cancer.

[Cancer Management and Research] A review of data from clinical trials on the use of carfilzomib, a second-generation PI, in the treatment of R/R multiple myeloma, as well as ongoing studies and prescribing advice.

Coverage from the American Society of Clinical Oncology 2019 meeting.

The following article features coverage from the American Society of Clinical Oncology 2019 meeting. Click here to read more of Oncology Nurse Advisor‘s conference coverage.